Related Experiment Video
Updated: Mar 18, 2026
12:33
High-throughput Fluorometric Measurement of Potential Soil Extracellular Enzyme Activities
Published on: November 15, 2013
48.7K
[Not Available]
Claire Chevreuil1, Elisabeth Polard2, Eric Lemonnier3
1Service de Psychiatrie Infanto-Juvénile, CH Guillaume Régnier, Rennes, France.
Therapie
|July 10, 2016
Summary
Aripiprazole, a novel antipsychotic, offers a unique mechanism for treating pediatric disorders. It demonstrates efficacy with a favorable safety profile, making it a valuable alternative for children and adolescents.
Area of Science:
- Neuroscience
- Pharmacology
Context:
- Aripiprazole represents a new class of antipsychotics: dopamine-serotonin system stabilizers.
- Its unique mechanism involves partial agonism at dopamine D2 and serotonin 5-HT1A receptors, and antagonism at 5-HT2A receptors.
Purpose:
- To evaluate the efficacy and safety of aripiprazole in pediatric populations across various psychiatric disorders.
- To highlight its distinct pharmacological profile compared to other second-generation antipsychotics.
Summary:
- Aripiprazole exhibits efficacy in treating bipolar disorders, schizophrenia, pervasive developmental disorders with mood issues, tics, and Tourette's in children and adolescents.
- Common side effects include dose-dependent extrapyramidal symptoms and somnolence.
- Notably, it causes minimal weight gain, does not affect lipid/glucidic profiles, prolactin levels, or QTc interval.
Impact:
- Aripiprazole presents a favorable safety profile, differentiating it from other available second-generation antipsychotics.
- It offers a crucial alternative for pediatric patients vulnerable to the adverse effects of traditional treatments.
